

## Neurolix Showcased in The Michael J. Fox Foundation's Partnering Program

**Dana Point, February 6, 2015** -- Neurolix today announced that it had been selected by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to be showcased in its Partnering Program.

The program presents promising MJFF portfolio projects directly to industry groups that may wish to invest in further development of the awardee's research. By promoting collaborations, MJFF aims to propel promising projects in Parkinson's disease (PD) research along the drug development pipeline. As Neurolix is an awardee, details of the company, its program and team are made available for review by industry groups.

Neurolix has received four grants from MJFF to support the study of NLX-112, its clinical candidate for the treatment of L-DOPA-induced dyskinesia (LID). NLX-112 exhibits a promising profile of activity in reducing and even eliminating dyskinesia in animal models of PD. Neurolix is currently exploring mechanisms to fund the clinical testing of NLX-112 in PD patients suffering from LID.

Dr. Mark A. Varney, CEO of Neurolix, commented: "We are delighted to be selected by MJFF to be part of the Partnering Program. NLX-112 has exciting potential to alleviate LID experienced by many PD patients as their disease progresses. The Foundation has been extremely supportive of our NLX-112 project, and its Partnering Program will provide Neurolix with valuable visibility as we build development collaborations on this drug."

"We believe the projects that we highlight in our Partnering Program are poised for further development," said Evelia Johnston, MJFF Research Partnerships Officer. "With larger funders who can offer more resources and greater experience in bringing drugs to market, drug candidates such as Neurolix' can accelerate toward clinical application for the five million worldwide living with Parkinson's."

The incidence of LID increases as PD progresses, and the longer PD patients are treated with L-DOPA. LID causes considerable discomfort and is a source of distress for patients and their families. No approved drug treatment for LID is currently available.

### **About Neurolix, Inc.**

Neurolix, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the central nervous system. The Company is focused on developing small molecule drugs for the treatment of neurological disorders such as Parkinson's disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at <http://www.neurolix.com>.

### **About The Michael J. Fox Foundation**

As the world's largest non-profit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than \$450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of

thousands of Team Fox members around the world. For more information, visit us on Facebook, Twitter, Web and LinkedIn.

### **Forward Looking Statement**

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolix disclaims any intent or obligation to update these forward-looking statements.

### **PRESS CONTACTS**

Dr Mark Varney, CEO Neurolix,  
mvarney@neurolix.com  
(949) 214-4017